BioCentury
ARTICLE | Emerging Company Profile

RORing against resistance

Why Oncternal’s ROR1 inhibitor could pair with BTK in chemo-resistant cancers

October 24, 2016 7:00 AM UTC

Oncternal Therapeutics Inc.’s ROR1 inhibitor could be combined with BTK inhibitors to increase response rates in chemotherapy-resistant or refractory hematologic cancers such as chronic lymphocytic leukemia and mantle cell lymphoma.

The Bruton’s tyrosine kinase (BTK) inhibitor Imbruvica ibrutinib from AbbVie Inc. and Johnson & Johnson is used to treat CLL and MCL after chemotherapy fails. ...